Literature DB >> 22646268

ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.

Neil E Fuehrer1, Gary L Keeney, Rhett P Ketterling, Ryan A Knudson, Debra A Bell.   

Abstract

CONTEXT: Inflammatory myofibroblastic tumor is a predominantly benign, spindle cell, mesenchymal neoplasm with myxoid areas that occurs rarely in the female genital tract and may be confused with other spindle cell lesions, particularly leiomyosarcoma.
OBJECTIVE: To investigate the utility of detecting anaplastic lymphoma kinase-1 protein expression and ALK gene rearrangements in the diagnosis of inflammatory myofibroblastic tumors in the female genital tract.
DESIGN: Eight inflammatory myofibroblastic tumors arising in the female genital tract and seen in consultation (from 2004 to 2011) were reviewed. Immunohistochemistry for anaplastic lymphoma kinase-1 and fluorescence in-situ hybridization studies for ALK gene rearrangements were performed.
RESULTS: The anatomic sites included myometrium (4 cases) and endometrium, fallopian tube, cervix, and a cervical polyp (1 each), with a patient age range from 25 to 52 years. Histologic features ranged from bland spindle cells to striking cytologic atypia, embedded in a prominent myxoid background. Anaplastic lymphoma kinase-1 immunohistochemistry was positive in 7 cases. Fluorescence in-situ hybridization studies detected ALK gene rearrangements in 5 cases. Five cases had both immunopositivity and fluorescence in-situ hybridization abnormalities, 2 cases had immunopositivity only, and 1 case was negative by both methods.
CONCLUSIONS: This is the first report, to our knowledge, of ALK gene rearrangements in inflammatory myofibroblastic tumors in the female genital tract. If a myxoid background is appreciated in a spindle cell lesion of the female genital tract, especially if inflammatory cells are present, anaplastic lymphoma kinase-1 staining along with fluorescence in situ hybridization studies, for ALK gene rearrangements, may aid in distinguishing inflammatory myofibroblastic tumors from their malignant mimics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22646268     DOI: 10.5858/arpa.2011-0341-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum.

Authors:  Jennifer A Bennett; Valentina Nardi; Marjan Rouzbahman; Vicente Morales-Oyarvide; G Petur Nielsen; Esther Oliva
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

2.  ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.

Authors:  Natasha Lewis; Robert A Soslow; Deborah F Delair; Kay J Park; Rajmohan Murali; Travis J Hollmann; Ben Davidson; Francesca Micci; Ioannis Panagopoulos; Lien N Hoang; Javier A Arias-Stella; Esther Oliva; Robert H Young; Martee L Hensley; Mario M Leitao; Meera Hameed; Ryma Benayed; Marc Ladanyi; Denise Frosina; Achim A Jungbluth; Cristina R Antonescu; Sarah Chiang
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

3.  Abdominopelvic inflammatory myofibroblastic tumor that metastasized to the vertebrae and liver: A case report and review of the literature.

Authors:  Sharon Kim; Jamie N Bakkum-Gamez; Scott Okuno; Sarah Kerr; Sean C Dowdy
Journal:  Gynecol Oncol Rep       Date:  2015-02-07

4.  STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Authors:  Vivek Subbiah; Caitlin McMahon; Shreyaskumar Patel; Ralph Zinner; Elvio G Silva; Julia A Elvin; Ishwaria M Subbiah; Chimela Ohaji; Dhakshina Moorthy Ganeshan; Deepa Anand; Charles F Levenback; Jenny Berry; Tim Brennan; Juliann Chmielecki; Zachary R Chalmers; John Mayfield; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2015-06-11       Impact factor: 17.388

5.  Inflammatory myofibroblastic tumor of salpinx: a very rare case treated with a less aggressive method.

Authors:  Fatemeh Homaei-Shandiz; Reza Jafarzadeh-Esfehani; Nasrin Moazzen; Amir Amirabadi
Journal:  Iran J Cancer Prev       Date:  2014

Review 6.  Uterine inflammatory myofibroblastic tumor: more common than expected: Case report and review.

Authors:  Vincenzo Dario Mandato; Riccardo Valli; Valentina Mastrofilippo; Alessandra Bisagni; Lorenzo Aguzzoli; Giovanni Battista La Sala
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

7.  Assessment of the potential diagnostic role of anaplastic lymphoma kinase for inflammatory myofibroblastic tumours: a meta-analysis.

Authors:  Shuiqing Wu; Ran Xu; Qi Wan; Xuan Zhu; Lei Zhang; Hongyi Jiang; Xiaokun Zhao
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

8.  Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.

Authors:  Akimasa Takahashi; Manabu Kurosawa; Mao Uemura; Jun Kitazawa; Yoshihiko Hayashi
Journal:  J Int Med Res       Date:  2018-06-14       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.